Triantafillidis JK. Surgical treatment of inflammatory bowel disease: From the gastroenterologist’s stand-point. World J Gastrointest Surg 2024; 16(5): 1235-1254 [PMID: 38817292 DOI: 10.4240/wjgs.v16.i5.1235]
Corresponding Author of This Article
John K Triantafillidis, FEBG, Professor, Inflammatory Bowel Disease Unit, “Metropolitan General” Hospital, 264 Mesogeion Avenue, Holargos 15562, Attica, Greece. jktrian@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. May 27, 2024; 16(5): 1235-1254 Published online May 27, 2024. doi: 10.4240/wjgs.v16.i5.1235
Surgical treatment of inflammatory bowel disease: From the gastroenterologist’s stand-point
John K Triantafillidis
John K Triantafillidis, Inflammatory Bowel Disease Unit, “Metropolitan General” Hospital, Holargos 15562, Attica, Greece
John K Triantafillidis, Hellenic Society of Gastrointestinal Oncology, Haidari 12461, Athens, Greece
Author contributions: Triantafillidis JK contributed to the design, writing, and revision of this manuscript.
Conflict-of-interest statement: The author reports no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: John K Triantafillidis, FEBG, Professor, Inflammatory Bowel Disease Unit, “Metropolitan General” Hospital, 264 Mesogeion Avenue, Holargos 15562, Attica, Greece. jktrian@gmail.com
Received: January 6, 2024 Revised: March 17, 2024 Accepted: April 24, 2024 Published online: May 27, 2024 Processing time: 137 Days and 16.8 Hours
Core Tip
Core Tip: The main indications for surgery in inflammatory bowel disease concern acute or chronic complications and/or failure of the conservative treatment. Emergency surgery in Crohn’s disease (CD) is performed in cases of intestinal obstruction, presence of perineal or intra-abdominal abscesses, and toxic colitis, while in patients with ulcerative colitis (UC) emergency surgery concerns bowel perforation, toxic megacolon, and uncontrolled bleeding. Elective surgery in CD concerns cases of strictures or perianal disease, while in patients with UC elective surgery is applied mainly in cases of patients unresponsive to conservative treatment. To achieve an excellent therapeutic result, the cooperation of a gastroenterologist, surgeon, pathologist, imaging physician, and nutritionist is necessary.
